JP2021514677A5 - - Google Patents
Info
- Publication number
- JP2021514677A5 JP2021514677A5 JP2020568943A JP2020568943A JP2021514677A5 JP 2021514677 A5 JP2021514677 A5 JP 2021514677A5 JP 2020568943 A JP2020568943 A JP 2020568943A JP 2020568943 A JP2020568943 A JP 2020568943A JP 2021514677 A5 JP2021514677 A5 JP 2021514677A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- domain
- cancer
- chimeric cytokine
- inducible chimeric
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024029998A JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637600P | 2018-03-02 | 2018-03-02 | |
| US62/637,600 | 2018-03-02 | ||
| PCT/US2019/020340 WO2019169290A1 (en) | 2018-03-02 | 2019-03-01 | Inducible chimeric cytokine receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029998A Division JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021514677A JP2021514677A (ja) | 2021-06-17 |
| JP2021514677A5 true JP2021514677A5 (https=) | 2022-03-10 |
| JPWO2019169290A5 JPWO2019169290A5 (https=) | 2022-03-10 |
| JP7526101B2 JP7526101B2 (ja) | 2024-07-31 |
Family
ID=65952060
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568943A Active JP7526101B2 (ja) | 2018-03-02 | 2019-03-01 | 誘導性キメラサイトカイン受容体 |
| JP2024029998A Active JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024029998A Active JP7793667B2 (ja) | 2018-03-02 | 2024-02-29 | 誘導性キメラサイトカイン受容体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12163169B2 (https=) |
| EP (1) | EP3759132A1 (https=) |
| JP (2) | JP7526101B2 (https=) |
| KR (2) | KR20250123938A (https=) |
| CN (1) | CN111819192A (https=) |
| AR (1) | AR114273A1 (https=) |
| AU (2) | AU2019227979B2 (https=) |
| BR (1) | BR112020017734A2 (https=) |
| CA (1) | CA3091681A1 (https=) |
| IL (2) | IL276831B2 (https=) |
| MX (2) | MX2020009051A (https=) |
| SG (1) | SG11202007771VA (https=) |
| TW (1) | TWI897846B (https=) |
| WO (1) | WO2019169290A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| EP3433269B1 (en) * | 2016-03-23 | 2023-09-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Fusion proteins of pd-1 and 4-1bb |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019169290A1 (en) * | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3844186A4 (en) * | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| BR112021017365A2 (pt) * | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| WO2021068068A1 (en) * | 2019-10-08 | 2021-04-15 | Provincial Health Services Authority | Chimeric cytokine receptors |
| CA3166420A1 (en) * | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Il2 orthologs and methods of use |
| JP2023514407A (ja) * | 2020-02-24 | 2023-04-05 | アロジーン セラピューティクス，インコーポレイテッド | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
| EP4110355A1 (en) * | 2020-02-24 | 2023-01-04 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer |
| CN115427440A (zh) | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| JP7748393B2 (ja) | 2020-05-08 | 2025-10-02 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 |
| AU2021308078A1 (en) * | 2020-07-17 | 2023-02-09 | Children's Hospital Los Angeles | Chimeric MyD88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| US20240052015A1 (en) * | 2020-12-23 | 2024-02-15 | Quell Therapeutics Limited | Inducible signalling protein |
| TW202246492A (zh) * | 2021-02-24 | 2022-12-01 | 中國大陸商杭州啟函生物科技有限公司 | 用於增強的免疫療法的系統和方法 |
| KR102829018B1 (ko) | 2021-03-03 | 2025-07-04 | 서울대학교산학협력단 | 키메릭 항원 수용체-대식 세포의 제조 방법 및 그 세포의 용도 |
| AU2022254143A1 (en) * | 2021-04-07 | 2023-11-23 | Provincial Health Services Authority | Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same |
| CN113512125B (zh) * | 2021-04-26 | 2024-01-19 | 北京双赢科创生物科技有限公司 | 一种携带stat结合基序的嵌合抗原受体分子及表达该嵌合抗原受体分子的nk细胞 |
| KR20240021179A (ko) * | 2021-05-14 | 2024-02-16 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 폴리펩티드 및 사용 방법 |
| WO2023276395A1 (ja) * | 2021-06-28 | 2023-01-05 | 愛知県 | キメラサイトカイン受容体 |
| WO2023044457A1 (en) | 2021-09-17 | 2023-03-23 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| CN118434761A (zh) | 2021-12-22 | 2024-08-02 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| CA3244596A1 (en) | 2022-03-29 | 2023-10-05 | Allogene Therapeutics, Inc. | Chimeric switch receivers for converting immunoactive signals into stimulation signals |
| JP2025525421A (ja) * | 2022-06-28 | 2025-08-05 | カリスマ セラピューティクス インコーポレイテッド | スイッチ受容体及び修飾免疫細胞 |
| US20250319131A1 (en) * | 2022-07-11 | 2025-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Tunable cytokine receptor signaling domains |
| CN114949000B (zh) * | 2022-08-02 | 2022-10-04 | 卡瑞济(北京)生命科技有限公司 | 麝香提取物及其增强car-t细胞疗效的应用 |
| CN117683139A (zh) * | 2022-09-09 | 2024-03-12 | 信达细胞制药(苏州)有限公司 | 组成型嵌合细胞因子受体及表达其的免疫细胞及应用 |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| KR20250169635A (ko) | 2023-01-23 | 2025-12-03 | 메디치니쉐 호흐슐레 하노버 | 항-entpd3 키메라 항원 수용체 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| IL322333A (en) | 2023-02-07 | 2025-09-01 | Quell Therapeutics Ltd | Culture method for TREG cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4669343A1 (en) | 2023-02-24 | 2025-12-31 | Medizinische Hochschule Hannover | CHIMERIC ANTIGEN RECIPIENT |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121586582A (zh) | 2023-03-20 | 2026-02-27 | 汉诺威医学院 | 嵌合抗原受体 |
| KR20260025162A (ko) | 2023-06-20 | 2026-02-23 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포의 검출 방법 |
| EP4731648A1 (en) | 2023-06-21 | 2026-04-29 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| CN121712794A (zh) * | 2023-06-29 | 2026-03-20 | 迪斯派奇生物治疗公司 | 合成细胞因子受体 |
| WO2025026347A1 (en) * | 2023-07-31 | 2025-02-06 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and methods of use thereof |
| WO2025064779A1 (en) * | 2023-09-20 | 2025-03-27 | University Of Southern California | Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others |
| WO2025076134A1 (en) * | 2023-10-03 | 2025-04-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use |
| WO2025096560A1 (en) | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025096643A1 (en) * | 2023-11-01 | 2025-05-08 | Baylor College Of Medicine | Reverse fate receptors to enhance the efficacy of engineered t cells |
| WO2025111277A2 (en) * | 2023-11-20 | 2025-05-30 | Carisma Therapeutics Inc. | Compositions and methods relating to redirected soluble modulators |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| IL114825A0 (en) | 1994-08-04 | 1995-12-08 | Regeneron Pharma | Rtk/cytokine receptor chimeras |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| WO1998002558A2 (en) * | 1996-07-17 | 1998-01-22 | University Of Medicine And Dentistry Of New Jersey | Chimeric receptors for jak-stat signal transduction |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| WO2007075899A2 (en) | 2005-12-21 | 2007-07-05 | Maxygen, Inc. | Dual agonist compounds and uses thereof |
| CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| EP2331680B1 (en) | 2008-09-22 | 2017-05-03 | Baylor College Of Medicine | Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters |
| WO2011069004A1 (en) | 2009-12-04 | 2011-06-09 | Quest Diagnostics Investments Incorporated | Mpl mutations in jak2 v617f negative patients with myeloproliferative disease |
| CN107164330A (zh) * | 2011-04-08 | 2017-09-15 | 贝勒医学院 | 使用嵌合细胞因子受体逆转肿瘤微环境的影响 |
| EP3549611B1 (en) | 2011-07-29 | 2021-06-30 | The Trustees of the University of Pennsylvania | Switch costimulatory receptors |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US9434935B2 (en) | 2013-03-10 | 2016-09-06 | Bellicum Pharmaceuticals, Inc. | Modified caspase polypeptides and uses thereof |
| WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| CA2912172A1 (en) | 2013-06-05 | 2014-12-11 | Bellicum Pharmaceuticals, Inc. | Methods for inducing partial apoptosis using caspase polypeptides |
| US10287354B2 (en) * | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| JP2017531430A (ja) * | 2014-10-07 | 2017-10-26 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｃａｒによって誘導される免疫細胞の活性を調節するための方法 |
| HK1245827B (en) | 2014-12-15 | 2020-06-19 | Board Of Regents Of The University Of Texas System | Methods for controlled activation or elimination of therapeutic cells |
| ES2869972T3 (es) | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| ES2857998T3 (es) * | 2015-02-12 | 2021-09-29 | Univ Health Network | Receptores de antígenos quiméricos |
| EP3283520B1 (en) | 2015-04-13 | 2020-05-06 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| CA2983004A1 (en) | 2015-04-15 | 2016-10-20 | Promedior, Inc. | Methods for treating myeloproliferative disorders |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| GB201518816D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| SG11201901642XA (en) | 2016-08-26 | 2019-03-28 | Baylor College Medicine | Constitutively active cytokine receptors for cell therapy |
| IL266628B2 (en) | 2016-11-17 | 2024-06-01 | Bluebird Bio Inc | TGFBeta signal converter |
| WO2018104473A1 (en) | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| GB201702617D0 (en) | 2017-02-17 | 2017-04-05 | Autolus Ltd | Receptor |
| AU2018226884B2 (en) | 2017-03-03 | 2024-11-07 | Exuma Biotech, Corp. | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof |
| CN111479921B (zh) * | 2017-09-18 | 2024-08-02 | 埃克苏马生物技术公司 | 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物 |
| GB201719557D0 (en) | 2017-11-24 | 2018-01-10 | Autolus Ltd | Polypeptide |
| WO2019118508A1 (en) | 2017-12-12 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting ny-eso-1 and methods of use thereof |
| WO2019169290A1 (en) * | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| TWI809130B (zh) | 2018-06-22 | 2023-07-21 | 美商凱特製藥公司 | 嵌合跨膜蛋白及其用途 |
| GB201814203D0 (en) | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| BR112021017365A2 (pt) | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
-
2019
- 2019-03-01 WO PCT/US2019/020340 patent/WO2019169290A1/en not_active Ceased
- 2019-03-01 KR KR1020257025809A patent/KR20250123938A/ko active Pending
- 2019-03-01 BR BR112020017734-2A patent/BR112020017734A2/pt unknown
- 2019-03-01 IL IL276831A patent/IL276831B2/en unknown
- 2019-03-01 IL IL317065A patent/IL317065A/en unknown
- 2019-03-01 SG SG11202007771VA patent/SG11202007771VA/en unknown
- 2019-03-01 KR KR1020207027009A patent/KR102842692B1/ko active Active
- 2019-03-01 EP EP19713907.4A patent/EP3759132A1/en active Pending
- 2019-03-01 JP JP2020568943A patent/JP7526101B2/ja active Active
- 2019-03-01 AR ARP190100529A patent/AR114273A1/es unknown
- 2019-03-01 US US16/290,388 patent/US12163169B2/en active Active
- 2019-03-01 AU AU2019227979A patent/AU2019227979B2/en active Active
- 2019-03-01 CN CN201980016890.6A patent/CN111819192A/zh active Pending
- 2019-03-01 CA CA3091681A patent/CA3091681A1/en active Pending
- 2019-03-01 MX MX2020009051A patent/MX2020009051A/es unknown
- 2019-03-04 TW TW108107136A patent/TWI897846B/zh active
-
2020
- 2020-08-31 MX MX2025009955A patent/MX2025009955A/es unknown
-
2024
- 2024-02-29 JP JP2024029998A patent/JP7793667B2/ja active Active
- 2024-10-16 US US18/917,035 patent/US20250333719A1/en active Pending
- 2024-12-04 AU AU2024278090A patent/AU2024278090A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514677A5 (https=) | ||
| IL276831B1 (en) | Inducible chimeric cytokine receptors | |
| JPWO2019169290A5 (https=) | ||
| JP2024074801A5 (https=) | ||
| JP7555625B2 (ja) | 治療用化合物及び方法 | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| TWI809130B (zh) | 嵌合跨膜蛋白及其用途 | |
| US20250043013A1 (en) | Nucleic acids encoding il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy | |
| EP3341410B1 (en) | Chimeric antigen receptors with integrated controllable functions | |
| CN114341193A (zh) | 包括tgfβ结合结构域的嵌合细胞因子受体 | |
| CN112955172A (zh) | 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途 | |
| CA2973529A1 (en) | Cll1-specific multi-chain chimeric antigen receptor | |
| JP2018509893A (ja) | キメラ抗原受容体 | |
| CN107428829A (zh) | 靶向g‑蛋白偶联受体的嵌合抗原受体及其用途 | |
| CN113811327A (zh) | MUC1平行CAR(pCAR)治疗剂 | |
| JP2025161810A (ja) | Ｉｌ－１スーパーファミリーのサイトカインの空間時間的に制限された活性が武装化された免疫応答性細胞 | |
| US12187776B2 (en) | Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor | |
| CN112996819B (zh) | 细胞分选系统及使用方法 | |
| JP2024511992A (ja) | ガンマデルタｔ細胞刺激 | |
| JP2021514188A (ja) | Ｆｏｘｐ３標的因子組成物と養子細胞療法のための使用方法 | |
| CA3144071A1 (en) | Chimeric protein expressing t-cells | |
| CN118108833A (zh) | 引入外源二硫键的tcr恒定区及其产品和应用 | |
| WO2026030667A1 (en) | Chimeric antigen receptors targeting the gamma delta t cell receptor | |
| HK1262734A1 (en) | Therapeutic compounds and methods |